nodes	percent_of_prediction	percent_of_DWPC	metapath
Bendroflumethiazide—KCNMA1—kidney cancer	0.5	0.65	CbGaD
Bendroflumethiazide—CA2—kidney cancer	0.27	0.35	CbGaD
Bendroflumethiazide—SLC12A3—collecting duct of renal tubule—kidney cancer	0.0282	0.329	CbGeAlD
Bendroflumethiazide—SLC12A3—nephron—kidney cancer	0.0126	0.146	CbGeAlD
Bendroflumethiazide—CA2—collecting duct of renal tubule—kidney cancer	0.0096	0.112	CbGeAlD
Bendroflumethiazide—CA4—Erythrocytes take up carbon dioxide and release oxygen—CA2—kidney cancer	0.00515	0.106	CbGpPWpGaD
Bendroflumethiazide—CA1—Erythrocytes take up carbon dioxide and release oxygen—CA2—kidney cancer	0.00474	0.0971	CbGpPWpGaD
Bendroflumethiazide—Hepatic encephalopathy—Paclitaxel—kidney cancer	0.00457	0.0513	CcSEcCtD
Bendroflumethiazide—CA4—Reversible hydration of carbon dioxide—CA2—kidney cancer	0.00409	0.0839	CbGpPWpGaD
Bendroflumethiazide—CA1—Reversible hydration of carbon dioxide—CA2—kidney cancer	0.00376	0.0771	CbGpPWpGaD
Bendroflumethiazide—Allergic cutaneous angiitis—Sorafenib—kidney cancer	0.00322	0.0362	CcSEcCtD
Bendroflumethiazide—CA4—Reversible hydration of carbon dioxide—CA9—kidney cancer	0.0031	0.0636	CbGpPWpGaD
Bendroflumethiazide—CA2—Reversible hydration of carbon dioxide—CA9—kidney cancer	0.00298	0.061	CbGpPWpGaD
Bendroflumethiazide—CA1—Reversible hydration of carbon dioxide—CA9—kidney cancer	0.00285	0.0585	CbGpPWpGaD
Bendroflumethiazide—SLC12A3—nephron tubule—kidney cancer	0.00271	0.0316	CbGeAlD
Bendroflumethiazide—SLC12A3—renal system—kidney cancer	0.00246	0.0287	CbGeAlD
Bendroflumethiazide—Leukocytoclastic vasculitis—Everolimus—kidney cancer	0.00241	0.0271	CcSEcCtD
Bendroflumethiazide—SLC12A3—kidney—kidney cancer	0.00238	0.0278	CbGeAlD
Bendroflumethiazide—SLC12A3—cortex of kidney—kidney cancer	0.00232	0.0271	CbGeAlD
Bendroflumethiazide—Epigastric discomfort—Everolimus—kidney cancer	0.00225	0.0252	CcSEcCtD
Bendroflumethiazide—Leukocytoclastic vasculitis—Sorafenib—kidney cancer	0.00209	0.0235	CcSEcCtD
Bendroflumethiazide—TPMT—nephron tubule—kidney cancer	0.00201	0.0235	CbGeAlD
Bendroflumethiazide—TPMT—renal system—kidney cancer	0.00183	0.0214	CbGeAlD
Bendroflumethiazide—Hypotensive—Paclitaxel—kidney cancer	0.00182	0.0204	CcSEcCtD
Bendroflumethiazide—TPMT—kidney—kidney cancer	0.00177	0.0207	CbGeAlD
Bendroflumethiazide—TPMT—cortex of kidney—kidney cancer	0.00172	0.0201	CbGeAlD
Bendroflumethiazide—KCNMA1—renal system—kidney cancer	0.0017	0.0199	CbGeAlD
Bendroflumethiazide—TPMT—gonad—kidney cancer	0.00164	0.0192	CbGeAlD
Bendroflumethiazide—TPMT—cardiac atrium—kidney cancer	0.00164	0.0191	CbGeAlD
Bendroflumethiazide—KCNMA1—gonad—kidney cancer	0.00153	0.0178	CbGeAlD
Bendroflumethiazide—Blood disorder—Everolimus—kidney cancer	0.00141	0.0159	CcSEcCtD
Bendroflumethiazide—Diabetes mellitus—Temsirolimus—kidney cancer	0.00132	0.0149	CcSEcCtD
Bendroflumethiazide—CA1—renal system—kidney cancer	0.00129	0.0151	CbGeAlD
Bendroflumethiazide—Gout—Everolimus—kidney cancer	0.00126	0.0142	CcSEcCtD
Bendroflumethiazide—CA1—kidney—kidney cancer	0.00125	0.0146	CbGeAlD
Bendroflumethiazide—Drug interaction—Erlotinib—kidney cancer	0.00123	0.0138	CcSEcCtD
Bendroflumethiazide—Blood disorder—Sunitinib—kidney cancer	0.00118	0.0133	CcSEcCtD
Bendroflumethiazide—TPMT—Biological oxidations—ACY1—kidney cancer	0.00114	0.0234	CbGpPWpGaD
Bendroflumethiazide—CA4—nephron tubule—kidney cancer	0.00111	0.013	CbGeAlD
Bendroflumethiazide—Drug interaction—Sorafenib—kidney cancer	0.0011	0.0124	CcSEcCtD
Bendroflumethiazide—Urine output increased—Everolimus—kidney cancer	0.00107	0.012	CcSEcCtD
Bendroflumethiazide—Hypokalaemia—Temsirolimus—kidney cancer	0.00105	0.0118	CcSEcCtD
Bendroflumethiazide—CA4—renal system—kidney cancer	0.00101	0.0118	CbGeAlD
Bendroflumethiazide—Diabetes mellitus—Everolimus—kidney cancer	0.000986	0.0111	CcSEcCtD
Bendroflumethiazide—CA4—kidney—kidney cancer	0.000978	0.0114	CbGeAlD
Bendroflumethiazide—Polyuria—Everolimus—kidney cancer	0.000976	0.011	CcSEcCtD
Bendroflumethiazide—CA4—cortex of kidney—kidney cancer	0.000952	0.0111	CbGeAlD
Bendroflumethiazide—CA2—nephron tubule—kidney cancer	0.000922	0.0108	CbGeAlD
Bendroflumethiazide—Pancreatitis—Pazopanib—kidney cancer	0.00092	0.0103	CcSEcCtD
Bendroflumethiazide—Hydroflumethiazide—KCNMA1—kidney cancer	0.000907	0.139	CrCbGaD
Bendroflumethiazide—CA4—cardiac atrium—kidney cancer	0.000906	0.0106	CbGeAlD
Bendroflumethiazide—Drug interaction—Vincristine—kidney cancer	0.000899	0.0101	CcSEcCtD
Bendroflumethiazide—Hydrochlorothiazide—KCNMA1—kidney cancer	0.000882	0.135	CrCbGaD
Bendroflumethiazide—Drug interaction—Gemcitabine—kidney cancer	0.000853	0.00959	CcSEcCtD
Bendroflumethiazide—CA2—renal system—kidney cancer	0.000839	0.00979	CbGeAlD
Bendroflumethiazide—CA2—kidney—kidney cancer	0.000811	0.00946	CbGeAlD
Bendroflumethiazide—Blood disorder—Paclitaxel—kidney cancer	0.000793	0.00891	CcSEcCtD
Bendroflumethiazide—CA2—cortex of kidney—kidney cancer	0.00079	0.00921	CbGeAlD
Bendroflumethiazide—Hypokalaemia—Everolimus—kidney cancer	0.00078	0.00876	CcSEcCtD
Bendroflumethiazide—Urine output increased—Vincristine—kidney cancer	0.000754	0.00847	CcSEcCtD
Bendroflumethiazide—Hypokalaemia—Erlotinib—kidney cancer	0.000753	0.00846	CcSEcCtD
Bendroflumethiazide—CA2—cardiac atrium—kidney cancer	0.000751	0.00876	CbGeAlD
Bendroflumethiazide—Pancreatitis—Everolimus—kidney cancer	0.000726	0.00816	CcSEcCtD
Bendroflumethiazide—Drug interaction—Paclitaxel—kidney cancer	0.000714	0.00803	CcSEcCtD
Bendroflumethiazide—Pancreatitis—Erlotinib—kidney cancer	0.000701	0.00787	CcSEcCtD
Bendroflumethiazide—Polyuria—Vincristine—kidney cancer	0.00069	0.00775	CcSEcCtD
Bendroflumethiazide—Erectile dysfunction—Everolimus—kidney cancer	0.000682	0.00767	CcSEcCtD
Bendroflumethiazide—Hypokalaemia—Sorafenib—kidney cancer	0.000677	0.00761	CcSEcCtD
Bendroflumethiazide—Hypokalaemia—Sunitinib—kidney cancer	0.000652	0.00732	CcSEcCtD
Bendroflumethiazide—Benzthiazide—CA9—kidney cancer	0.000649	0.0992	CrCbGaD
Bendroflumethiazide—Pancreatitis—Sorafenib—kidney cancer	0.000631	0.00708	CcSEcCtD
Bendroflumethiazide—Muscle spasms—Pazopanib—kidney cancer	0.000629	0.00706	CcSEcCtD
Bendroflumethiazide—TPMT—Phase II conjugation—GSTT1—kidney cancer	0.000628	0.0129	CbGpPWpGaD
Bendroflumethiazide—TPMT—Biological oxidations—ALDH1A1—kidney cancer	0.000626	0.0128	CbGpPWpGaD
Bendroflumethiazide—Pancreatitis—Sunitinib—kidney cancer	0.000607	0.00682	CcSEcCtD
Bendroflumethiazide—KCNMA1—Platelet homeostasis—ITPR2—kidney cancer	0.000603	0.0124	CbGpPWpGaD
Bendroflumethiazide—Urine output increased—Paclitaxel—kidney cancer	0.000599	0.00673	CcSEcCtD
Bendroflumethiazide—Erectile dysfunction—Sorafenib—kidney cancer	0.000592	0.00665	CcSEcCtD
Bendroflumethiazide—Benzthiazide—CA2—kidney cancer	0.000583	0.0892	CrCbGaD
Bendroflumethiazide—Cyclothiazide—CA2—kidney cancer	0.000583	0.0892	CrCbGaD
Bendroflumethiazide—Thrombocytopenia—Temsirolimus—kidney cancer	0.000555	0.00623	CcSEcCtD
Bendroflumethiazide—Polyuria—Paclitaxel—kidney cancer	0.000548	0.00615	CcSEcCtD
Bendroflumethiazide—Hydroflumethiazide—CA9—kidney cancer	0.000544	0.0832	CrCbGaD
Bendroflumethiazide—Anorexia—Temsirolimus—kidney cancer	0.00054	0.00607	CcSEcCtD
Bendroflumethiazide—CA1—C-MYB transcription factor network—CD34—kidney cancer	0.000536	0.011	CbGpPWpGaD
Bendroflumethiazide—Hydrochlorothiazide—CA9—kidney cancer	0.000529	0.0809	CrCbGaD
Bendroflumethiazide—Hypokalaemia—Gemcitabine—kidney cancer	0.000523	0.00587	CcSEcCtD
Bendroflumethiazide—Thrombocytopenia—Pazopanib—kidney cancer	0.000522	0.00587	CcSEcCtD
Bendroflumethiazide—Anorexia—Pazopanib—kidney cancer	0.000509	0.00571	CcSEcCtD
Bendroflumethiazide—Muscle spasms—Everolimus—kidney cancer	0.000496	0.00558	CcSEcCtD
Bendroflumethiazide—Decreased appetite—Temsirolimus—kidney cancer	0.000492	0.00553	CcSEcCtD
Bendroflumethiazide—Urine output increased—Capecitabine—kidney cancer	0.000492	0.00552	CcSEcCtD
Bendroflumethiazide—Hydroflumethiazide—CA2—kidney cancer	0.000489	0.0748	CrCbGaD
Bendroflumethiazide—Constipation—Temsirolimus—kidney cancer	0.000484	0.00544	CcSEcCtD
Bendroflumethiazide—Erectile dysfunction—Vincristine—kidney cancer	0.000482	0.00542	CcSEcCtD
Bendroflumethiazide—Hydrochlorothiazide—CA2—kidney cancer	0.000476	0.0727	CrCbGaD
Bendroflumethiazide—Trichlormethiazide—CA9—kidney cancer	0.000471	0.0721	CrCbGaD
Bendroflumethiazide—Decreased appetite—Pazopanib—kidney cancer	0.000464	0.00521	CcSEcCtD
Bendroflumethiazide—Diabetes mellitus—Capecitabine—kidney cancer	0.000454	0.0051	CcSEcCtD
Bendroflumethiazide—Polyuria—Capecitabine—kidney cancer	0.00045	0.00505	CcSEcCtD
Bendroflumethiazide—Vascular purpura—Capecitabine—kidney cancer	0.000441	0.00496	CcSEcCtD
Bendroflumethiazide—Orthostatic hypotension—Paclitaxel—kidney cancer	0.000439	0.00494	CcSEcCtD
Bendroflumethiazide—Hypokalaemia—Paclitaxel—kidney cancer	0.000438	0.00492	CcSEcCtD
Bendroflumethiazide—TPMT—Phase II conjugation—GSTP1—kidney cancer	0.000436	0.00893	CbGpPWpGaD
Bendroflumethiazide—Cramp muscle—Paclitaxel—kidney cancer	0.000433	0.00487	CcSEcCtD
Bendroflumethiazide—Muscle spasms—Sorafenib—kidney cancer	0.000431	0.00484	CcSEcCtD
Bendroflumethiazide—SLC12A3—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—kidney cancer	0.000426	0.00874	CbGpPWpGaD
Bendroflumethiazide—Trichlormethiazide—CA2—kidney cancer	0.000424	0.0648	CrCbGaD
Bendroflumethiazide—Blood disorder—Doxorubicin—kidney cancer	0.00042	0.00471	CcSEcCtD
Bendroflumethiazide—Thirst—Capecitabine—kidney cancer	0.000415	0.00466	CcSEcCtD
Bendroflumethiazide—Muscle spasms—Sunitinib—kidney cancer	0.000415	0.00466	CcSEcCtD
Bendroflumethiazide—Thrombocytopenia—Vinblastine—kidney cancer	0.000414	0.00465	CcSEcCtD
Bendroflumethiazide—Thrombocytopenia—Everolimus—kidney cancer	0.000413	0.00463	CcSEcCtD
Bendroflumethiazide—Purpura—Capecitabine—kidney cancer	0.00041	0.0046	CcSEcCtD
Bendroflumethiazide—Pancreatitis—Paclitaxel—kidney cancer	0.000408	0.00458	CcSEcCtD
Bendroflumethiazide—Asthenia—Temsirolimus—kidney cancer	0.000406	0.00457	CcSEcCtD
Bendroflumethiazide—Anorexia—Vinblastine—kidney cancer	0.000403	0.00453	CcSEcCtD
Bendroflumethiazide—Anorexia—Everolimus—kidney cancer	0.000402	0.00451	CcSEcCtD
Bendroflumethiazide—TPMT—Phase II conjugation—GSTM1—kidney cancer	0.0004	0.0082	CbGpPWpGaD
Bendroflumethiazide—Thrombocytopenia—Erlotinib—kidney cancer	0.000398	0.00447	CcSEcCtD
Bendroflumethiazide—Hypotension—Everolimus—kidney cancer	0.000394	0.00442	CcSEcCtD
Bendroflumethiazide—Diarrhoea—Temsirolimus—kidney cancer	0.000388	0.00435	CcSEcCtD
Bendroflumethiazide—Anorexia—Erlotinib—kidney cancer	0.000387	0.00435	CcSEcCtD
Bendroflumethiazide—Asthenia—Pazopanib—kidney cancer	0.000383	0.0043	CcSEcCtD
Bendroflumethiazide—Dizziness—Temsirolimus—kidney cancer	0.000375	0.00421	CcSEcCtD
Bendroflumethiazide—TPMT—Biological oxidations—GSTT1—kidney cancer	0.000368	0.00753	CbGpPWpGaD
Bendroflumethiazide—Decreased appetite—Vinblastine—kidney cancer	0.000368	0.00413	CcSEcCtD
Bendroflumethiazide—Decreased appetite—Everolimus—kidney cancer	0.000366	0.00411	CcSEcCtD
Bendroflumethiazide—Diarrhoea—Pazopanib—kidney cancer	0.000365	0.0041	CcSEcCtD
Bendroflumethiazide—Constipation—Vinblastine—kidney cancer	0.000362	0.00406	CcSEcCtD
Bendroflumethiazide—SLC12A3—SLC-mediated transmembrane transport—SLC5A3—kidney cancer	0.000361	0.0074	CbGpPWpGaD
Bendroflumethiazide—Orthostatic hypotension—Capecitabine—kidney cancer	0.000361	0.00405	CcSEcCtD
Bendroflumethiazide—Constipation—Everolimus—kidney cancer	0.00036	0.00405	CcSEcCtD
Bendroflumethiazide—Vomiting—Temsirolimus—kidney cancer	0.00036	0.00405	CcSEcCtD
Bendroflumethiazide—Hypokalaemia—Capecitabine—kidney cancer	0.000359	0.00404	CcSEcCtD
Bendroflumethiazide—Thrombocytopenia—Sorafenib—kidney cancer	0.000358	0.00402	CcSEcCtD
Bendroflumethiazide—KCNMA1—Circadian rythm related genes—HNF1B—kidney cancer	0.000358	0.00733	CbGpPWpGaD
Bendroflumethiazide—Rash—Temsirolimus—kidney cancer	0.000357	0.00401	CcSEcCtD
Bendroflumethiazide—Dermatitis—Temsirolimus—kidney cancer	0.000357	0.00401	CcSEcCtD
Bendroflumethiazide—Decreased appetite—Erlotinib—kidney cancer	0.000353	0.00397	CcSEcCtD
Bendroflumethiazide—Dizziness—Pazopanib—kidney cancer	0.000353	0.00396	CcSEcCtD
Bendroflumethiazide—Anorexia—Sorafenib—kidney cancer	0.000349	0.00392	CcSEcCtD
Bendroflumethiazide—Constipation—Erlotinib—kidney cancer	0.000348	0.00391	CcSEcCtD
Bendroflumethiazide—Thrombocytopenia—Sunitinib—kidney cancer	0.000345	0.00387	CcSEcCtD
Bendroflumethiazide—TPMT—Biological oxidations—PTGS1—kidney cancer	0.000345	0.00706	CbGpPWpGaD
Bendroflumethiazide—Vomiting—Pazopanib—kidney cancer	0.000339	0.00381	CcSEcCtD
Bendroflumethiazide—Rash—Pazopanib—kidney cancer	0.000336	0.00378	CcSEcCtD
Bendroflumethiazide—Nausea—Temsirolimus—kidney cancer	0.000336	0.00378	CcSEcCtD
Bendroflumethiazide—Dermatitis—Pazopanib—kidney cancer	0.000336	0.00378	CcSEcCtD
Bendroflumethiazide—Anorexia—Sunitinib—kidney cancer	0.000335	0.00377	CcSEcCtD
Bendroflumethiazide—Thrombocytopenia—Dactinomycin—kidney cancer	0.000326	0.00366	CcSEcCtD
Bendroflumethiazide—SLC12A3—Transmembrane transport of small molecules—RYR1—kidney cancer	0.00032	0.00655	CbGpPWpGaD
Bendroflumethiazide—Decreased appetite—Sorafenib—kidney cancer	0.000318	0.00357	CcSEcCtD
Bendroflumethiazide—Anorexia—Dactinomycin—kidney cancer	0.000318	0.00357	CcSEcCtD
Bendroflumethiazide—Nausea—Pazopanib—kidney cancer	0.000317	0.00356	CcSEcCtD
Bendroflumethiazide—Constipation—Sorafenib—kidney cancer	0.000313	0.00351	CcSEcCtD
Bendroflumethiazide—KCNMA1—Circadian rythm related genes—JUND—kidney cancer	0.000313	0.00641	CbGpPWpGaD
Bendroflumethiazide—Decreased appetite—Sunitinib—kidney cancer	0.000306	0.00344	CcSEcCtD
Bendroflumethiazide—Asthenia—Vinblastine—kidney cancer	0.000303	0.00341	CcSEcCtD
Bendroflumethiazide—Asthenia—Everolimus—kidney cancer	0.000302	0.0034	CcSEcCtD
Bendroflumethiazide—Constipation—Sunitinib—kidney cancer	0.000301	0.00338	CcSEcCtD
Bendroflumethiazide—Diabetes mellitus—Doxorubicin—kidney cancer	0.000293	0.00329	CcSEcCtD
Bendroflumethiazide—Asthenia—Erlotinib—kidney cancer	0.000292	0.00328	CcSEcCtD
Bendroflumethiazide—Thrombocytopenia—Vincristine—kidney cancer	0.000291	0.00327	CcSEcCtD
Bendroflumethiazide—Decreased appetite—Dactinomycin—kidney cancer	0.00029	0.00325	CcSEcCtD
Bendroflumethiazide—Diarrhoea—Vinblastine—kidney cancer	0.000289	0.00325	CcSEcCtD
Bendroflumethiazide—Diarrhoea—Everolimus—kidney cancer	0.000288	0.00324	CcSEcCtD
Bendroflumethiazide—Vascular purpura—Doxorubicin—kidney cancer	0.000284	0.0032	CcSEcCtD
Bendroflumethiazide—Anorexia—Vincristine—kidney cancer	0.000284	0.00319	CcSEcCtD
Bendroflumethiazide—Dizziness—Vinblastine—kidney cancer	0.00028	0.00314	CcSEcCtD
Bendroflumethiazide—Dizziness—Everolimus—kidney cancer	0.000279	0.00313	CcSEcCtD
Bendroflumethiazide—Muscle spasms—Paclitaxel—kidney cancer	0.000278	0.00313	CcSEcCtD
Bendroflumethiazide—Diarrhoea—Erlotinib—kidney cancer	0.000278	0.00312	CcSEcCtD
Bendroflumethiazide—Hypotension—Vincristine—kidney cancer	0.000278	0.00312	CcSEcCtD
Bendroflumethiazide—Thrombocytopenia—Gemcitabine—kidney cancer	0.000276	0.00311	CcSEcCtD
Bendroflumethiazide—CA1—C-MYB transcription factor network—GSTM1—kidney cancer	0.000276	0.00566	CbGpPWpGaD
Bendroflumethiazide—Anorexia—Gemcitabine—kidney cancer	0.000269	0.00302	CcSEcCtD
Bendroflumethiazide—Vomiting—Vinblastine—kidney cancer	0.000269	0.00302	CcSEcCtD
Bendroflumethiazide—Dizziness—Erlotinib—kidney cancer	0.000269	0.00302	CcSEcCtD
Bendroflumethiazide—Vomiting—Everolimus—kidney cancer	0.000268	0.00301	CcSEcCtD
Bendroflumethiazide—Rash—Everolimus—kidney cancer	0.000266	0.00298	CcSEcCtD
Bendroflumethiazide—Dermatitis—Everolimus—kidney cancer	0.000265	0.00298	CcSEcCtD
Bendroflumethiazide—KCNMA1—Hemostasis—L1CAM—kidney cancer	0.000265	0.00543	CbGpPWpGaD
Bendroflumethiazide—Purpura—Doxorubicin—kidney cancer	0.000264	0.00297	CcSEcCtD
Bendroflumethiazide—Hypotension—Gemcitabine—kidney cancer	0.000264	0.00296	CcSEcCtD
Bendroflumethiazide—Asthenia—Sorafenib—kidney cancer	0.000262	0.00295	CcSEcCtD
Bendroflumethiazide—Decreased appetite—Vincristine—kidney cancer	0.000259	0.00291	CcSEcCtD
Bendroflumethiazide—Vomiting—Erlotinib—kidney cancer	0.000258	0.0029	CcSEcCtD
Bendroflumethiazide—Rash—Erlotinib—kidney cancer	0.000256	0.00288	CcSEcCtD
Bendroflumethiazide—Dermatitis—Erlotinib—kidney cancer	0.000256	0.00288	CcSEcCtD
Bendroflumethiazide—TPMT—Biological oxidations—GSTP1—kidney cancer	0.000255	0.00522	CbGpPWpGaD
Bendroflumethiazide—Constipation—Vincristine—kidney cancer	0.000255	0.00286	CcSEcCtD
Bendroflumethiazide—Asthenia—Sunitinib—kidney cancer	0.000252	0.00284	CcSEcCtD
Bendroflumethiazide—TPMT—Metapathway biotransformation—GSTP1—kidney cancer	0.000251	0.00515	CbGpPWpGaD
Bendroflumethiazide—Nausea—Vinblastine—kidney cancer	0.000251	0.00282	CcSEcCtD
Bendroflumethiazide—Nausea—Everolimus—kidney cancer	0.00025	0.00281	CcSEcCtD
Bendroflumethiazide—Diarrhoea—Sorafenib—kidney cancer	0.00025	0.00281	CcSEcCtD
Bendroflumethiazide—Decreased appetite—Gemcitabine—kidney cancer	0.000245	0.00276	CcSEcCtD
Bendroflumethiazide—Dizziness—Sorafenib—kidney cancer	0.000242	0.00272	CcSEcCtD
Bendroflumethiazide—Constipation—Gemcitabine—kidney cancer	0.000241	0.00271	CcSEcCtD
Bendroflumethiazide—Nausea—Erlotinib—kidney cancer	0.000241	0.00271	CcSEcCtD
Bendroflumethiazide—Diarrhoea—Sunitinib—kidney cancer	0.000241	0.00271	CcSEcCtD
Bendroflumethiazide—Asthenia—Dactinomycin—kidney cancer	0.000239	0.00269	CcSEcCtD
Bendroflumethiazide—TPMT—Biological oxidations—GSTM1—kidney cancer	0.000234	0.0048	CbGpPWpGaD
Bendroflumethiazide—Dizziness—Sunitinib—kidney cancer	0.000233	0.00261	CcSEcCtD
Bendroflumethiazide—Vomiting—Sorafenib—kidney cancer	0.000233	0.00261	CcSEcCtD
Bendroflumethiazide—Orthostatic hypotension—Doxorubicin—kidney cancer	0.000232	0.00261	CcSEcCtD
Bendroflumethiazide—Hypokalaemia—Doxorubicin—kidney cancer	0.000232	0.0026	CcSEcCtD
Bendroflumethiazide—Thrombocytopenia—Paclitaxel—kidney cancer	0.000231	0.0026	CcSEcCtD
Bendroflumethiazide—TPMT—Metapathway biotransformation—GSTM1—kidney cancer	0.000231	0.00473	CbGpPWpGaD
Bendroflumethiazide—Rash—Sorafenib—kidney cancer	0.000231	0.00259	CcSEcCtD
Bendroflumethiazide—Dermatitis—Sorafenib—kidney cancer	0.00023	0.00259	CcSEcCtD
Bendroflumethiazide—Muscle spasms—Capecitabine—kidney cancer	0.000229	0.00257	CcSEcCtD
Bendroflumethiazide—Diarrhoea—Dactinomycin—kidney cancer	0.000228	0.00256	CcSEcCtD
Bendroflumethiazide—Anorexia—Paclitaxel—kidney cancer	0.000225	0.00253	CcSEcCtD
Bendroflumethiazide—Vomiting—Sunitinib—kidney cancer	0.000224	0.00251	CcSEcCtD
Bendroflumethiazide—TPMT—Biological oxidations—CYP1A1—kidney cancer	0.000222	0.00455	CbGpPWpGaD
Bendroflumethiazide—Rash—Sunitinib—kidney cancer	0.000222	0.00249	CcSEcCtD
Bendroflumethiazide—Dermatitis—Sunitinib—kidney cancer	0.000222	0.00249	CcSEcCtD
Bendroflumethiazide—Hypotension—Paclitaxel—kidney cancer	0.000221	0.00248	CcSEcCtD
Bendroflumethiazide—TPMT—Metapathway biotransformation—CYP1A1—kidney cancer	0.000219	0.00449	CbGpPWpGaD
Bendroflumethiazide—Nausea—Sorafenib—kidney cancer	0.000217	0.00244	CcSEcCtD
Bendroflumethiazide—Pancreatitis—Doxorubicin—kidney cancer	0.000216	0.00242	CcSEcCtD
Bendroflumethiazide—Asthenia—Vincristine—kidney cancer	0.000214	0.0024	CcSEcCtD
Bendroflumethiazide—Vomiting—Dactinomycin—kidney cancer	0.000212	0.00238	CcSEcCtD
Bendroflumethiazide—Rash—Dactinomycin—kidney cancer	0.00021	0.00236	CcSEcCtD
Bendroflumethiazide—Nausea—Sunitinib—kidney cancer	0.000209	0.00235	CcSEcCtD
Bendroflumethiazide—Decreased appetite—Paclitaxel—kidney cancer	0.000206	0.00231	CcSEcCtD
Bendroflumethiazide—CA1—C-MYB transcription factor network—KIT—kidney cancer	0.000205	0.0042	CbGpPWpGaD
Bendroflumethiazide—Diarrhoea—Vincristine—kidney cancer	0.000204	0.00229	CcSEcCtD
Bendroflumethiazide—Asthenia—Gemcitabine—kidney cancer	0.000203	0.00228	CcSEcCtD
Bendroflumethiazide—Constipation—Paclitaxel—kidney cancer	0.000202	0.00227	CcSEcCtD
Bendroflumethiazide—KCNMA1—Hemostasis—ANXA2—kidney cancer	0.000201	0.00412	CbGpPWpGaD
Bendroflumethiazide—KCNMA1—Circadian rythm related genes—EGR1—kidney cancer	0.000199	0.00408	CbGpPWpGaD
Bendroflumethiazide—KCNMA1—Neuronal System—ACHE—kidney cancer	0.000198	0.00406	CbGpPWpGaD
Bendroflumethiazide—Nausea—Dactinomycin—kidney cancer	0.000198	0.00222	CcSEcCtD
Bendroflumethiazide—Dizziness—Vincristine—kidney cancer	0.000197	0.00221	CcSEcCtD
Bendroflumethiazide—TPMT—Metabolism—ACY1—kidney cancer	0.000195	0.004	CbGpPWpGaD
Bendroflumethiazide—Diarrhoea—Gemcitabine—kidney cancer	0.000193	0.00217	CcSEcCtD
Bendroflumethiazide—SLC12A3—SLC-mediated transmembrane transport—SLC5A5—kidney cancer	0.00019	0.0039	CbGpPWpGaD
Bendroflumethiazide—Thrombocytopenia—Capecitabine—kidney cancer	0.00019	0.00213	CcSEcCtD
Bendroflumethiazide—Vomiting—Vincristine—kidney cancer	0.000189	0.00213	CcSEcCtD
Bendroflumethiazide—Rash—Vincristine—kidney cancer	0.000188	0.00211	CcSEcCtD
Bendroflumethiazide—Dermatitis—Vincristine—kidney cancer	0.000187	0.00211	CcSEcCtD
Bendroflumethiazide—Anorexia—Capecitabine—kidney cancer	0.000185	0.00208	CcSEcCtD
Bendroflumethiazide—SLC12A3—SLC-mediated transmembrane transport—SLC2A1—kidney cancer	0.000184	0.00377	CbGpPWpGaD
Bendroflumethiazide—SLC12A3—Transmembrane transport of small molecules—ATP7B—kidney cancer	0.000184	0.00376	CbGpPWpGaD
Bendroflumethiazide—SLC12A3—Transmembrane transport of small molecules—SLC5A3—kidney cancer	0.000184	0.00376	CbGpPWpGaD
Bendroflumethiazide—SLC12A3—Transmembrane transport of small molecules—ANXA2—kidney cancer	0.000184	0.00376	CbGpPWpGaD
Bendroflumethiazide—Hypotension—Capecitabine—kidney cancer	0.000181	0.00204	CcSEcCtD
Bendroflumethiazide—Vomiting—Gemcitabine—kidney cancer	0.00018	0.00202	CcSEcCtD
Bendroflumethiazide—Rash—Gemcitabine—kidney cancer	0.000178	0.002	CcSEcCtD
Bendroflumethiazide—Dermatitis—Gemcitabine—kidney cancer	0.000178	0.002	CcSEcCtD
Bendroflumethiazide—Nausea—Vincristine—kidney cancer	0.000177	0.00199	CcSEcCtD
Bendroflumethiazide—KCNMA1—Neuronal System—BCHE—kidney cancer	0.000173	0.00354	CbGpPWpGaD
Bendroflumethiazide—Asthenia—Paclitaxel—kidney cancer	0.00017	0.00191	CcSEcCtD
Bendroflumethiazide—Decreased appetite—Capecitabine—kidney cancer	0.000169	0.00189	CcSEcCtD
Bendroflumethiazide—Nausea—Gemcitabine—kidney cancer	0.000168	0.00188	CcSEcCtD
Bendroflumethiazide—CA1—C-MYB transcription factor network—CDKN2A—kidney cancer	0.000166	0.00341	CbGpPWpGaD
Bendroflumethiazide—TPMT—Metabolism—PDHB—kidney cancer	0.000166	0.0034	CbGpPWpGaD
Bendroflumethiazide—Constipation—Capecitabine—kidney cancer	0.000166	0.00186	CcSEcCtD
Bendroflumethiazide—TPMT—Biological oxidations—POMC—kidney cancer	0.000166	0.00339	CbGpPWpGaD
Bendroflumethiazide—Diarrhoea—Paclitaxel—kidney cancer	0.000162	0.00182	CcSEcCtD
Bendroflumethiazide—CA1—C-MYB transcription factor network—CD4—kidney cancer	0.000157	0.00321	CbGpPWpGaD
Bendroflumethiazide—Dizziness—Paclitaxel—kidney cancer	0.000156	0.00176	CcSEcCtD
Bendroflumethiazide—TPMT—Metabolism—CCBL1—kidney cancer	0.000156	0.0032	CbGpPWpGaD
Bendroflumethiazide—CA1—C-MYB transcription factor network—PTGS2—kidney cancer	0.000156	0.00319	CbGpPWpGaD
Bendroflumethiazide—Vomiting—Paclitaxel—kidney cancer	0.00015	0.00169	CcSEcCtD
Bendroflumethiazide—Rash—Paclitaxel—kidney cancer	0.000149	0.00167	CcSEcCtD
Bendroflumethiazide—Dermatitis—Paclitaxel—kidney cancer	0.000149	0.00167	CcSEcCtD
Bendroflumethiazide—CA1—C-MYB transcription factor network—CDKN1B—kidney cancer	0.000147	0.00302	CbGpPWpGaD
Bendroflumethiazide—Muscle spasms—Doxorubicin—kidney cancer	0.000147	0.00166	CcSEcCtD
Bendroflumethiazide—KCNMA1—Hemostasis—GRB7—kidney cancer	0.000145	0.00298	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—ACY1—kidney cancer	0.000141	0.00289	CbGpPWpGaD
Bendroflumethiazide—CA1—C-MYB transcription factor network—CCND1—kidney cancer	0.000141	0.00288	CbGpPWpGaD
Bendroflumethiazide—Nausea—Paclitaxel—kidney cancer	0.00014	0.00158	CcSEcCtD
Bendroflumethiazide—Asthenia—Capecitabine—kidney cancer	0.000139	0.00156	CcSEcCtD
Bendroflumethiazide—TPMT—Metabolism—PPAT—kidney cancer	0.000135	0.00277	CbGpPWpGaD
Bendroflumethiazide—CA2—Metabolism—ACY1—kidney cancer	0.000135	0.00277	CbGpPWpGaD
Bendroflumethiazide—TPMT—Metabolism—GLIPR1—kidney cancer	0.000135	0.00277	CbGpPWpGaD
Bendroflumethiazide—KCNMA1—Hemostasis—ITPR2—kidney cancer	0.000135	0.00277	CbGpPWpGaD
Bendroflumethiazide—Diarrhoea—Capecitabine—kidney cancer	0.000133	0.00149	CcSEcCtD
Bendroflumethiazide—CA1—Metabolism—ACY1—kidney cancer	0.00013	0.00266	CbGpPWpGaD
Bendroflumethiazide—Dizziness—Capecitabine—kidney cancer	0.000128	0.00144	CcSEcCtD
Bendroflumethiazide—TPMT—Metabolism—APRT—kidney cancer	0.000126	0.00258	CbGpPWpGaD
Bendroflumethiazide—TPMT—Metabolism—FH—kidney cancer	0.000126	0.00258	CbGpPWpGaD
Bendroflumethiazide—Vomiting—Capecitabine—kidney cancer	0.000123	0.00139	CcSEcCtD
Bendroflumethiazide—Thrombocytopenia—Doxorubicin—kidney cancer	0.000122	0.00138	CcSEcCtD
Bendroflumethiazide—Rash—Capecitabine—kidney cancer	0.000122	0.00137	CcSEcCtD
Bendroflumethiazide—Dermatitis—Capecitabine—kidney cancer	0.000122	0.00137	CcSEcCtD
Bendroflumethiazide—CA4—Metabolism—PDHB—kidney cancer	0.00012	0.00246	CbGpPWpGaD
Bendroflumethiazide—Anorexia—Doxorubicin—kidney cancer	0.000119	0.00134	CcSEcCtD
Bendroflumethiazide—TPMT—Metabolism—GPC3—kidney cancer	0.000118	0.00242	CbGpPWpGaD
Bendroflumethiazide—Hypotension—Doxorubicin—kidney cancer	0.000117	0.00131	CcSEcCtD
Bendroflumethiazide—Nausea—Capecitabine—kidney cancer	0.000115	0.00129	CcSEcCtD
Bendroflumethiazide—CA2—Metabolism—PDHB—kidney cancer	0.000115	0.00236	CbGpPWpGaD
Bendroflumethiazide—TPMT—Metabolism—CA2—kidney cancer	0.000115	0.00236	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—CCBL1—kidney cancer	0.000113	0.00231	CbGpPWpGaD
Bendroflumethiazide—CA1—C-MYB transcription factor network—MYC—kidney cancer	0.000113	0.00231	CbGpPWpGaD
Bendroflumethiazide—TPMT—Metabolism—ALAD—kidney cancer	0.000112	0.0023	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—PDHB—kidney cancer	0.00011	0.00226	CbGpPWpGaD
Bendroflumethiazide—TPMT—Metabolism—ST3GAL2—kidney cancer	0.000109	0.00224	CbGpPWpGaD
Bendroflumethiazide—Decreased appetite—Doxorubicin—kidney cancer	0.000109	0.00122	CcSEcCtD
Bendroflumethiazide—CA2—Metabolism—CCBL1—kidney cancer	0.000108	0.00222	CbGpPWpGaD
Bendroflumethiazide—TPMT—Metabolism—ALDH1A1—kidney cancer	0.000107	0.00219	CbGpPWpGaD
Bendroflumethiazide—Constipation—Doxorubicin—kidney cancer	0.000107	0.0012	CcSEcCtD
Bendroflumethiazide—CA1—C-MYB transcription factor network—KRAS—kidney cancer	0.000104	0.00214	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—CCBL1—kidney cancer	0.000104	0.00213	CbGpPWpGaD
Bendroflumethiazide—TPMT—Metabolism—PGK1—kidney cancer	0.000103	0.0021	CbGpPWpGaD
Bendroflumethiazide—TPMT—Metabolism—SLC5A3—kidney cancer	0.000103	0.0021	CbGpPWpGaD
Bendroflumethiazide—TPMT—Metabolism—LDHB—kidney cancer	0.000101	0.00206	CbGpPWpGaD
Bendroflumethiazide—KCNMA1—Hemostasis—IFNA1—kidney cancer	9.92e-05	0.00203	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—GLIPR1—kidney cancer	9.79e-05	0.00201	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—PPAT—kidney cancer	9.79e-05	0.00201	CbGpPWpGaD
Bendroflumethiazide—SLC12A3—Transmembrane transport of small molecules—SLC5A5—kidney cancer	9.68e-05	0.00198	CbGpPWpGaD
Bendroflumethiazide—CA2—Metabolism—PPAT—kidney cancer	9.38e-05	0.00192	CbGpPWpGaD
Bendroflumethiazide—CA2—Metabolism—GLIPR1—kidney cancer	9.38e-05	0.00192	CbGpPWpGaD
Bendroflumethiazide—SLC12A3—Transmembrane transport of small molecules—SLC2A1—kidney cancer	9.35e-05	0.00192	CbGpPWpGaD
Bendroflumethiazide—KCNMA1—Hemostasis—IFNA2—kidney cancer	9.23e-05	0.00189	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—FH—kidney cancer	9.1e-05	0.00186	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—APRT—kidney cancer	9.1e-05	0.00186	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—GLIPR1—kidney cancer	9e-05	0.00184	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—PPAT—kidney cancer	9e-05	0.00184	CbGpPWpGaD
Bendroflumethiazide—Asthenia—Doxorubicin—kidney cancer	8.97e-05	0.00101	CcSEcCtD
Bendroflumethiazide—KCNMA1—Neuronal System—BRAF—kidney cancer	8.82e-05	0.00181	CbGpPWpGaD
Bendroflumethiazide—CA2—Metabolism—FH—kidney cancer	8.72e-05	0.00179	CbGpPWpGaD
Bendroflumethiazide—CA2—Metabolism—APRT—kidney cancer	8.72e-05	0.00179	CbGpPWpGaD
Bendroflumethiazide—TPMT—Metabolism—CA9—kidney cancer	8.72e-05	0.00179	CbGpPWpGaD
Bendroflumethiazide—Diarrhoea—Doxorubicin—kidney cancer	8.56e-05	0.000961	CcSEcCtD
Bendroflumethiazide—CA4—Metabolism—GPC3—kidney cancer	8.55e-05	0.00175	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—APRT—kidney cancer	8.36e-05	0.00171	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—FH—kidney cancer	8.36e-05	0.00171	CbGpPWpGaD
Bendroflumethiazide—KCNMA1—Circadian rythm related genes—JUN—kidney cancer	8.35e-05	0.00171	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—CA2—kidney cancer	8.32e-05	0.00171	CbGpPWpGaD
Bendroflumethiazide—KCNMA1—Hemostasis—IGF2—kidney cancer	8.31e-05	0.0017	CbGpPWpGaD
Bendroflumethiazide—Dizziness—Doxorubicin—kidney cancer	8.27e-05	0.000929	CcSEcCtD
Bendroflumethiazide—CA2—Metabolism—GPC3—kidney cancer	8.2e-05	0.00168	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—ALAD—kidney cancer	8.11e-05	0.00166	CbGpPWpGaD
Bendroflumethiazide—KCNMA1—Circadian rythm related genes—PTEN—kidney cancer	8.07e-05	0.00165	CbGpPWpGaD
Bendroflumethiazide—Vomiting—Doxorubicin—kidney cancer	7.95e-05	0.000893	CcSEcCtD
Bendroflumethiazide—CA4—Metabolism—ST3GAL2—kidney cancer	7.91e-05	0.00162	CbGpPWpGaD
Bendroflumethiazide—Rash—Doxorubicin—kidney cancer	7.88e-05	0.000886	CcSEcCtD
Bendroflumethiazide—Dermatitis—Doxorubicin—kidney cancer	7.88e-05	0.000885	CcSEcCtD
Bendroflumethiazide—CA1—Metabolism—GPC3—kidney cancer	7.86e-05	0.00161	CbGpPWpGaD
Bendroflumethiazide—CA2—Metabolism—ALAD—kidney cancer	7.77e-05	0.00159	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—ALDH1A1—kidney cancer	7.74e-05	0.00159	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—CA2—kidney cancer	7.65e-05	0.00157	CbGpPWpGaD
Bendroflumethiazide—CA2—Metabolism—ST3GAL2—kidney cancer	7.59e-05	0.00155	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—ALAD—kidney cancer	7.45e-05	0.00153	CbGpPWpGaD
Bendroflumethiazide—Nausea—Doxorubicin—kidney cancer	7.43e-05	0.000835	CcSEcCtD
Bendroflumethiazide—CA2—Metabolism—ALDH1A1—kidney cancer	7.42e-05	0.00152	CbGpPWpGaD
Bendroflumethiazide—TPMT—Metabolism—CRABP1—kidney cancer	7.42e-05	0.00152	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—SLC5A3—kidney cancer	7.42e-05	0.00152	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—PGK1—kidney cancer	7.42e-05	0.00152	CbGpPWpGaD
Bendroflumethiazide—SLC12A3—Transmembrane transport of small molecules—ABCB1—kidney cancer	7.38e-05	0.00151	CbGpPWpGaD
Bendroflumethiazide—KCNMA1—Neuronal System—RAF1—kidney cancer	7.36e-05	0.00151	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—ST3GAL2—kidney cancer	7.27e-05	0.00149	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—LDHB—kidney cancer	7.27e-05	0.00149	CbGpPWpGaD
Bendroflumethiazide—CA2—Metabolism—SLC5A3—kidney cancer	7.11e-05	0.00146	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—ALDH1A1—kidney cancer	7.11e-05	0.00146	CbGpPWpGaD
Bendroflumethiazide—CA2—Metabolism—PGK1—kidney cancer	7.11e-05	0.00146	CbGpPWpGaD
Bendroflumethiazide—CA2—Metabolism—LDHB—kidney cancer	6.97e-05	0.00143	CbGpPWpGaD
Bendroflumethiazide—TPMT—Metabolism—ITPR2—kidney cancer	6.89e-05	0.00141	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—PGK1—kidney cancer	6.82e-05	0.0014	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—SLC5A3—kidney cancer	6.82e-05	0.0014	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—LDHB—kidney cancer	6.69e-05	0.00137	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—CA9—kidney cancer	6.31e-05	0.00129	CbGpPWpGaD
Bendroflumethiazide—TPMT—Metabolism—ACHE—kidney cancer	6.29e-05	0.00129	CbGpPWpGaD
Bendroflumethiazide—TPMT—Metabolism—GSTT1—kidney cancer	6.29e-05	0.00129	CbGpPWpGaD
Bendroflumethiazide—CA2—Metabolism—CA9—kidney cancer	6.05e-05	0.00124	CbGpPWpGaD
Bendroflumethiazide—TPMT—Metabolism—SCARB1—kidney cancer	5.95e-05	0.00122	CbGpPWpGaD
Bendroflumethiazide—TPMT—Metabolism—PTGS1—kidney cancer	5.89e-05	0.00121	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—CA9—kidney cancer	5.8e-05	0.00119	CbGpPWpGaD
Bendroflumethiazide—TPMT—Metabolism—PSMD7—kidney cancer	5.78e-05	0.00118	CbGpPWpGaD
Bendroflumethiazide—KCNMA1—Circadian rythm related genes—TP53—kidney cancer	5.51e-05	0.00113	CbGpPWpGaD
Bendroflumethiazide—TPMT—Metabolism—BCHE—kidney cancer	5.48e-05	0.00112	CbGpPWpGaD
Bendroflumethiazide—TPMT—Metabolism—SLC5A5—kidney cancer	5.41e-05	0.00111	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—CRABP1—kidney cancer	5.36e-05	0.0011	CbGpPWpGaD
Bendroflumethiazide—TPMT—Metabolism—SLC2A1—kidney cancer	5.23e-05	0.00107	CbGpPWpGaD
Bendroflumethiazide—CA2—Metabolism—CRABP1—kidney cancer	5.14e-05	0.00105	CbGpPWpGaD
Bendroflumethiazide—KCNMA1—Neuronal System—MAPK1—kidney cancer	5.05e-05	0.00103	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—ITPR2—kidney cancer	4.98e-05	0.00102	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—CRABP1—kidney cancer	4.93e-05	0.00101	CbGpPWpGaD
Bendroflumethiazide—CA2—Metabolism—ITPR2—kidney cancer	4.78e-05	0.000979	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—ITPR2—kidney cancer	4.58e-05	0.000939	CbGpPWpGaD
Bendroflumethiazide—KCNMA1—Hemostasis—RAF1—kidney cancer	4.57e-05	0.000937	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—GSTT1—kidney cancer	4.55e-05	0.000932	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—ACHE—kidney cancer	4.55e-05	0.000932	CbGpPWpGaD
Bendroflumethiazide—TPMT—Metabolism—GSTP1—kidney cancer	4.36e-05	0.000893	CbGpPWpGaD
Bendroflumethiazide—CA2—Metabolism—ACHE—kidney cancer	4.36e-05	0.000893	CbGpPWpGaD
Bendroflumethiazide—CA2—Metabolism—GSTT1—kidney cancer	4.36e-05	0.000893	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—SCARB1—kidney cancer	4.3e-05	0.000882	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—PTGS1—kidney cancer	4.26e-05	0.000873	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—ACHE—kidney cancer	4.18e-05	0.000856	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—GSTT1—kidney cancer	4.18e-05	0.000856	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—PSMD7—kidney cancer	4.18e-05	0.000856	CbGpPWpGaD
Bendroflumethiazide—SLC12A3—Transmembrane transport of small molecules—RAF1—kidney cancer	4.18e-05	0.000856	CbGpPWpGaD
Bendroflumethiazide—CA2—Metabolism—SCARB1—kidney cancer	4.13e-05	0.000845	CbGpPWpGaD
Bendroflumethiazide—TPMT—Metabolism—ABCB1—kidney cancer	4.13e-05	0.000845	CbGpPWpGaD
Bendroflumethiazide—KCNMA1—Hemostasis—IL2—kidney cancer	4.1e-05	0.00084	CbGpPWpGaD
Bendroflumethiazide—CA2—Metabolism—PTGS1—kidney cancer	4.08e-05	0.000837	CbGpPWpGaD
Bendroflumethiazide—CA2—Metabolism—PSMD7—kidney cancer	4e-05	0.000821	CbGpPWpGaD
Bendroflumethiazide—TPMT—Metabolism—GSTM1—kidney cancer	4e-05	0.000821	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—BCHE—kidney cancer	3.96e-05	0.000812	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—SCARB1—kidney cancer	3.96e-05	0.000811	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—PTGS1—kidney cancer	3.92e-05	0.000802	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—SLC5A5—kidney cancer	3.91e-05	0.000802	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—PSMD7—kidney cancer	3.84e-05	0.000787	CbGpPWpGaD
Bendroflumethiazide—CA2—Metabolism—BCHE—kidney cancer	3.8e-05	0.000778	CbGpPWpGaD
Bendroflumethiazide—TPMT—Metabolism—CYP1A1—kidney cancer	3.8e-05	0.000778	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—SLC2A1—kidney cancer	3.78e-05	0.000774	CbGpPWpGaD
Bendroflumethiazide—CA2—Metabolism—SLC5A5—kidney cancer	3.75e-05	0.000769	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—BCHE—kidney cancer	3.64e-05	0.000746	CbGpPWpGaD
Bendroflumethiazide—CA2—Metabolism—SLC2A1—kidney cancer	3.62e-05	0.000742	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—SLC5A5—kidney cancer	3.6e-05	0.000737	CbGpPWpGaD
Bendroflumethiazide—KCNMA1—Hemostasis—VEGFA—kidney cancer	3.48e-05	0.000714	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—SLC2A1—kidney cancer	3.47e-05	0.000712	CbGpPWpGaD
Bendroflumethiazide—KCNMA1—Hemostasis—MAPK3—kidney cancer	3.3e-05	0.000676	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—GSTP1—kidney cancer	3.15e-05	0.000646	CbGpPWpGaD
Bendroflumethiazide—KCNMA1—Hemostasis—MAPK1—kidney cancer	3.14e-05	0.000643	CbGpPWpGaD
Bendroflumethiazide—CA2—Metabolism—GSTP1—kidney cancer	3.02e-05	0.000619	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—ABCB1—kidney cancer	2.98e-05	0.000611	CbGpPWpGaD
Bendroflumethiazide—KCNMA1—Hemostasis—KRAS—kidney cancer	2.96e-05	0.000607	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—GSTP1—kidney cancer	2.9e-05	0.000594	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—GSTM1—kidney cancer	2.9e-05	0.000593	CbGpPWpGaD
Bendroflumethiazide—CA2—Metabolism—ABCB1—kidney cancer	2.86e-05	0.000586	CbGpPWpGaD
Bendroflumethiazide—TPMT—Metabolism—POMC—kidney cancer	2.83e-05	0.00058	CbGpPWpGaD
Bendroflumethiazide—CA2—Metabolism—GSTM1—kidney cancer	2.78e-05	0.000569	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—CYP1A1—kidney cancer	2.74e-05	0.000563	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—ABCB1—kidney cancer	2.74e-05	0.000562	CbGpPWpGaD
Bendroflumethiazide—KCNMA1—Hemostasis—PIK3CA—kidney cancer	2.72e-05	0.000558	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—GSTM1—kidney cancer	2.66e-05	0.000545	CbGpPWpGaD
Bendroflumethiazide—KCNMA1—Hemostasis—TP53—kidney cancer	2.63e-05	0.00054	CbGpPWpGaD
Bendroflumethiazide—CA2—Metabolism—CYP1A1—kidney cancer	2.63e-05	0.000539	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—CYP1A1—kidney cancer	2.52e-05	0.000517	CbGpPWpGaD
Bendroflumethiazide—TPMT—Metabolism—PTGS2—kidney cancer	2.26e-05	0.000463	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—POMC—kidney cancer	2.05e-05	0.000419	CbGpPWpGaD
Bendroflumethiazide—TPMT—Metabolism—PTEN—kidney cancer	1.97e-05	0.000404	CbGpPWpGaD
Bendroflumethiazide—CA2—Metabolism—POMC—kidney cancer	1.96e-05	0.000402	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—POMC—kidney cancer	1.88e-05	0.000385	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—PTGS2—kidney cancer	1.63e-05	0.000335	CbGpPWpGaD
Bendroflumethiazide—CA2—Metabolism—PTGS2—kidney cancer	1.56e-05	0.000321	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—PTGS2—kidney cancer	1.5e-05	0.000307	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—PTEN—kidney cancer	1.42e-05	0.000292	CbGpPWpGaD
Bendroflumethiazide—TPMT—Metabolism—PIK3CA—kidney cancer	1.39e-05	0.000285	CbGpPWpGaD
Bendroflumethiazide—CA2—Metabolism—PTEN—kidney cancer	1.36e-05	0.00028	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—PTEN—kidney cancer	1.31e-05	0.000268	CbGpPWpGaD
Bendroflumethiazide—CA4—Metabolism—PIK3CA—kidney cancer	1e-05	0.000206	CbGpPWpGaD
Bendroflumethiazide—CA2—Metabolism—PIK3CA—kidney cancer	9.63e-06	0.000197	CbGpPWpGaD
Bendroflumethiazide—CA1—Metabolism—PIK3CA—kidney cancer	9.23e-06	0.000189	CbGpPWpGaD
